Abstract-The effects of propranolol on lipid metabolism were studied in spon taneously hypertensive rats (SHR).
Propranolol, a potent beta ad re n erg Ic blocking agent, has been used widely in the treatment of angina pectoris, hypertension and various arrhythmias. Recently, many clinicians have recognized the possible adverse effect of long-term treatment with beta-blocking agents on lipid metabolism. In former studies, increases in human plasma triglycerides after administration of propranolol were reported (1) (2) (3) (4) . However, the same findings were not duplicated in studies on animal species. We previously reported the low plasma tri glyceride level in normotensive Sprague Dawley rats after treatment with propranolol (5) . The purpose of this paper is to describe the chronic effect of propranolol on serum, liver and aortic lipids in spontaneously hypertensive rats (SHR). SHR are a strain of Wistar Kyoto rat which had been developed by Okamoto and Aoki (6) . This animal model appears to be a suitable model for human essential hypertension and is now available as a genetically pure strain (7) .
Materials and Methods
Animals and drug administration: Male normotensive rats of the Wistar Kyoto (WKY) strain and male spontaneously hypertensive rats (SHR), developed by Okamoto and Aoki (6), were used. Four-week-old (80-90 g) WKY and SHR of the F38 generation were divided into three groups: a WKY group, a SHR group and a propranolol-treated SH R group (SHR-P); each group consisted of five rats. Rats were fed a stock diet (M F, Oriental Kobo Co. Ltd.), and they were kept under standard laboratory conditions. WKY and SHR groups were given distilled water, 0.2 ml/100 g/day by gavage, and the SHR-P group was given propranolol, 10 mg/kg/day by the same means. Treatment was started at 5 weeks of age and continued up to 1 5 weeks of age.
Measurments of heart rate and blood pressure: Heart rate and blood pressure were determined weekly prior to drug adminis tration using the rat method with Natsume KN 209.
Preparation of sample for biochemical determinations:
Rats were anesthesized with pentobarbital sodium (40 mg/kg, i. p.) between 9-12 a.m., after 12 hr of fasting. Blood was drawn from the inferior vena cava by a syringe, and the liver and thoracic aorta were removed. Serum, liver and aortic lipid levels of rats in each group were examined on the third day and at two-week intervals after treatment. The lipid fraction of the liver and aorta were extracted by the Bragdon method (8) (HDL-PL) in the serum were separated by a dextran sulfate magnesium precipitation method (15). HDL C in the serum was determined by the modified Rosenthal method (9) and HDL-PL in the serum was determined by an enzymatic spectrophotometric method (10). Serum glucose was measured by the o-toluidine borate method (16), and serum insulin was measured by radioimmunoassay (17). 
Results
Heart rate and blood pressure: Heart rate in both WKY and SHR groups varied; however, the rate in the SHR group was slightly higher than that in the WKY group. At the 6th week of treatment with pro pranolol, heart rate in the SHR-P group decreased significantly compared to that in the SHR group.
Blood pressure in the WKY group increased gradually until 9 weeks of age; however, it subsequently remained between 120 and 130 mmHg.
Blood pressure in the SHR group was slightly higher than that in the WKY group, even at 5 weeks of age. Blood pressure in the SHR group increased rapidly after 7 weeks of age and reached the highest level of 170 to 180 mmHg. At the 4th week of treatment with propranolol, blood pressure in the SHR-P group was significantly lower compared to that in the SHR group (Fig. I) .
Body weight: Body weight gains in the SHR and SHR-P groups were significantly lower than in the WKY group at the 2nd week of treatment. However, there was no sig nificant difference in the body weight gain of SHR and SHR-P groups (Fig. 2) .
Variation in serum lipid levels: As shown in Figs. 3 and 4 , time-dependent changes were observed in rat serum lipid levels through 10 weeks of treatment with pro pranolol. Serum TC level decreased with age in the SHR group and was significantly higher in the SHR-P group than in the SHR group. However, there was no significant difference between WKY and SHR groups in serum TC. Serum PL level decreased with age in the SHR group, and it was slightly higher in the SHR-P group than in the SHR group (Fig. 3) . However, at the 6th week of treatment with propranolol, HDL-C and HDL-PL levels were 39.8±6.0 mg/dl and 54.3±5.0 mg/dl in the WKY group, 42.3±4.7 mg/dI and 52.6± 2.8 mg/dl in the SHR group, and 41.5±3.4 mg/dl and 57.1±5.3 mg/dl in the SHR-P group, respectively; these levels were not significantly different among the three groups.
Serum TG and NEFA levels in the SHR group were low, compared to those in the WKY group in the early weeks of adminis tration. They were slightly lower in the SHR P group than in the SHR group in the early weeks of treatment with propranolol, but there was no difference among the three groups at the 8th and 10th weeks of treat ment with propranolol (Fig. 4) . At the 6th week of treatment with pro pranolol, serum FC level was 4.67±0.53 mg/ dl in the WKY group, 4.88±1.20 mg/dl in the SHR group, and 6.26±1.24 mg/dl in the SHR-P group, respectively, and these levels were not significantly different among the three groups.
At the 6th week of treatment with pro pranolol, the serum atherogenic cholesterol (18) were 0.46±0.16 and 0.37±0.07 in the WKY group, 0.38±0.11 and 0.26±0.11 in the SHR group, and 0.62±0. 15 and 0.37 ±0 .12 in the SHR-P group. The serum atherogenic cholesterol index in the SHR-P group was significantly higher than in the SHR group (P<0.05); however, the other index was not significantly different among the three groups.
Variation in liver and aortic lipid levels: At the 6th week of treatment with pro pranolol, liver TC and TL levels were 3.47± 0.58 mg/g and 43.6±4.2 mg/g in the WKY group, 3.63±0.44 mg/g and 43.2±4.8 mg/g in the SHR group, and 3.94±0.63 mg/g and 46.4±5.6 mg/g in the SHR-P group, respec tively. These levels were not significantly different among the three groups.
Time-dependent changes in aortic lipid levels in the three groups through 10 weeks of treatment with propranolol are shown in Figs. 5 and 6. Aortic TC in the SHR group was significantly lower than in the WKY group in the later weeks of treatment, but there was no significant difference between SHR and SHR-P groups. Aortic PL in the SHR group was significantly lower than in the WKY group at the 8th and 10th weeks of treat ment; however, there was no significant difference between SHR and SHR-P groups (Fig. 5) .
Aortic TG and TL in the SHR-P group were significantly lower than those in the SHR group in the early weeks of treatment (Fig. 6) .
Serum immunoreactive insulin values and blood glucose levels: Time-dependent changes in serum immunoreactive insulin values and blood glucose levels through 10 weeks of treatment with propranolol are shown in Fig. 7 .
Serum immunoreactive insulin values in the SHR group was lower than in the WKY group in the later weeks of treatment, especially at the 10th week of treatment. These values in the SHR-P group were slightly lower than in the SHR group in the later weeks of treatment with propranolol.
Blood glucose level in the WKY group was significantly lower than in the SHR group at the 4th week of treatment, and it was sig nificantly higher in the SHR-P group than in the SHR group at the 10th week of treat ment with propranolol (Fig. 7) . In general, the serum lipid levels in the SHR group were low compared to that in the WKY group. Yamori et al. gain. The present study showed that body weight gain was significantly lower in SHR and SHR-P groups than in the WKY group. These phenomena suggest that serum lipid levels might be correlated with body weight gain.
In the present study, early changes in lipids were observed despite the lack of hemodynamic changes during propranolol treatment. That is, serum TG and NEFA levels in the SHR-P group were slightly lower than those in the SHR group in the early weeks of treatment. These phenomena sug gest that propranolol may have inhibited adenylate cyclase activity as well as hydrolysis of TG in adipose tissue. Previously, Yasuhara et al. (5) reported that serum NEFA and TG in normotensive rats treated with propranolol was low compared to that in untreated normo tensive rats. However, there was no difference between SHR and SHR-P groups in the later weeks of treatment with propranolol. That is, the tendency for the serum NEFA level to increase suggests that propranolol may have inhibited beta-oxidation of NEFA (14) and re-esterification of NEFA to TG (24); also, this tendency for the serum TG level to increase suggests that lipoprotein catabolism (LPL activity) may have been inhibited by propranolol.
Therefore, it seems likely that these levels in the SHR-P group might be higher than in the SHR group if that group were treated with propranolol after 10 weeks. Our results also demonstrated that serum TC in the SHR-P group was significantly higher than in the SHR group. This suggests that propranolol may have either enhanced cholesterol biosynthesis and/or inhibited cholesterol catabolism. At the 10th week of treatment with pro pranolol, serum immunoreactive insulin value in the SHR-P group was slightly lower than in the SHR group, and the blood glucose level in the SHR-P group was higher than in the SHR group. Charles et al. (25) showed that fasting insulin concentrations fell by 70% during beta-adrenergic blockade, whereas blood glucose remained unchanged during beta-adrenergic blockade. Further more, Akerblom et al. (26) reported that the serum immunoreactive insulin values and blood glucose levels in propranolol treated rats were lower than those in Wistar rats. Birnbaum et al. (27) reported that propranolol induced elevation in basal serum glucose concentrations and decreased glucose tolerance at 2.5 and 3 hr. However, there was no noticeable effect on insulin secretion, although insulin secretion is known to be decreased by other beta-blockers in man (28) .
Our results showed a propranolol-induced decrease in serum immunoreactive insulin value. This insulin decrease might inhibit incorporation of glucose into the tissue.
In conclusion, propranolol increased serum TC and decreased serum TG and NEFA levels in SHR. These results failed to cor respond with previous studies reporting increases in serum TG after administration of propranolol to humans (3, 4, 19, 29, 30) . These phenomena suggest that propranolol may inhibit hormone sensitive lipase activity and may influence cholesterol biosynthesis and/or catabolism. Further study will be required to clarify the mechanisms.
